ST Germain D J Co. Inc. Grows Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

ST Germain D J Co. Inc. raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2,712.1% during the first quarter, HoldingsChannel reports. The firm owned 10,658 shares of the medical research company’s stock after buying an additional 10,279 shares during the period. ST Germain D J Co. Inc.’s holdings in Thermo Fisher Scientific were worth $6,195,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. Park National Corp OH acquired a new stake in Thermo Fisher Scientific during the 1st quarter worth approximately $207,000. Canandaigua National Bank & Trust Co. grew its position in Thermo Fisher Scientific by 20.9% in the 1st quarter. Canandaigua National Bank & Trust Co. now owns 9,269 shares of the medical research company’s stock valued at $5,387,000 after buying an additional 1,605 shares during the last quarter. Confluence Investment Management LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at $50,683,000. Nomura Holdings Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $15,005,000. Finally, HighPoint Advisor Group LLC acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $6,582,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $70,873,516.56. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at $7,430,359.02. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,000 shares of company stock valued at $12,532,780. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.2 %

NYSE:TMO traded up $1.17 on Tuesday, reaching $569.17. The stock had a trading volume of 1,398,060 shares, compared to its average volume of 1,486,346. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a 50-day moving average of $574.95 and a 200 day moving average of $559.33. The stock has a market cap of $217.26 billion, a P/E ratio of 36.43, a price-to-earnings-growth ratio of 2.67 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be paid a dividend of $0.39 per share. The ex-dividend date is Friday, June 14th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on TMO. HSBC upped their price objective on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Jefferies Financial Group reissued a “buy” rating and issued a $650.00 price target (up from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. JPMorgan Chase & Co. raised their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Citigroup began coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $607.94.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.